Table 45

Transfusion and Thromboembolic Event Rates from Trials on Thresholds for Initiating Therapy

studyN evalua-ted (for transfusion)drug and treatment durationHb when EPO/DARB initiated% patients given EPO/DARB% transfusedrelative risk of transfusion95% confidence intervalthrombo-embolic events (%)
I1D1I1D1I1D1I1D1I1D1
Straus 2003 135134epoetin
16 weeks
11.1 ± 0.73<910019.417.826.10.680.43, 1.08113*
Rearden 2004 99102darbepoetin
12 weeks2
11.1 ± 0.74<1010062.717.226.50.650.38, 1.1121
Crawford 2003 106105epoetin
16 weeks
13.1 ± 1.03<101004412.321.00.590.31, 1.10NR5NR5
1

I = erythropoietic stimulant therapy begun immediately after randomization; D = erythropoietic stimulant therapy delayed until Hb falls to threshold;

2

transfusion data include 22 weeks followup as patients received chemotherapy throughout;

3

mean ± standard deviation;

4

mean ± standard error;

5

“…no differences between groups in frequency or pattern of adverse events…”;

*

statistically significant difference; NR=not reported

From: 3, Results

Cover of Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet].
Comparative Effectiveness Reviews, No. 3.
Seidenfeld J, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.